Teva asks US Supreme Court to stay ruling in Copaxone case 25 NEWS
LSIPR Newsletter 04:14 WASHINGTON, DC, US
Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone (glatiramer acetate).
Te application comes a week aſter the Supreme Court agreed to hear Teva’s appeal against the Federal Circuit decision in its case against two generic pharmaceutical company teams seeking to launch their own versions of Copaxone: Sandoz and Momenta, and Mylan and Natco.
In July last year, the Federal Circuit invalidated a patent covering Copaxone, allowing generic drug makers to enter the market on May 24, 2014, the day the remaining Copaxone patents expire.
Te invalidated patent was due to expire on September 1, 2015.
In its application to stay the appeals court’s ruling, Teva said the Supreme Court’s intervention was needed before the May date “to ensure that its decision on the merits next term will not come effectively too late to prevent irreparable harm to Teva”.
Te case is due to be heard by the Supreme Court when the next term begins in October. A decision on the case may not be handed down until early 2015, by which time competitors’ products could have been on the market for nearly a year.
Teva’s prior requests to stay the ruling had been denied, although it argued that now “there is at least a fair prospect—if not a strong probability— of reversal” of the appeals court’s decision.
It added: “Accordingly, Teva should not now be leſt without the injunction that the District Court granted to protect Teva against irreparable harm.”
Teva told LSIPR that it has no further comment related to the litigation. n
See Copaxone case study, p18
Supreme Court decides
LSIPR Newsletter 02:14 NEWS 7
HOW TO FORTIFY YOUR INNOVATIONS, IDEAS AND TRADEMARKS
Innovations, models and trademarks are a valuable asset in any business. They enhance a company’s distinguishing capacity, boost its impact, strengthen its competitive position and make it more attractive to investors. Therefore, there is every reason to give Intellectual Property a prominent place in your business strategy. We can support you by protecting and enriching your innovations, models and trademarks, thanks to our extensive range of services and the expertise of our trademark, design and patent specialists who find solutions where others don’t. We are the largest consultancy in Intellectual Property in the Netherlands and one of the most pioneering firms in Europe. If you would like to know more, visit
www.nlo.nl
www.lifesciencesipreview.com
www.lifesciencesipreview.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24